ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alisertib

Also written as “Alisertib”, “[^14C]-alisertib” and “Alisertib (MLN8237)”.

Its studies are mostly in Lymphoma · Small Cell Lung Carcinoma · Breast Neoplasms · Ovarian Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Drug pageMLN 8237: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 28, 201124 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only200 open or runningphase 3since Nov 28, 2011Jul 12, 2007none ahead
Puma Biotechnologyits history only33 open or runningphase 2since Sep 27, 2023Sep 27, 2023Oct 30, 2027phase 2 · NCT06095505
Sarah Cannon Research Institute10 open or runningphase 2since Jul 6, 2014Jul 6, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sarah Cannon Research Institute only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2014First study: phase 2 study in Breast NeoplasmsFirst studyNCT02187991 · 169 enrolled · United States

TargetBeta

AURKA →read by rule
“Serine/threonine-protein kinase Aurora-A inhibitor”ChEMBL 37, by rule

Studies

The one study Sarah Cannon Research Institute leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02187991Breast Neoplasms · United States2CompletedApr 11, 2024169

How it is read

Names in the registry

  • “Alisertib”, 23 entries
  • “alisertib”, 2 entries
  • “[^14C]-alisertib”, 1 entry
  • “Alisertib (MLN8237)”, 1 entry
  • “MLN8237 (Alisertib)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.